Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Adamis Pharmaceuticals Corporation is a drug manufacturers-specialty & generic business based in the US. Adamis Pharmaceuticals Corporation shares (ADMP) are listed on the NASDAQ and all prices are listed in US Dollars. Adamis Pharmaceuticals Corporation employs 116 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.09|
|52-week range||$0.39 - $1.80|
|50-day moving average||$1.06|
|200-day moving average||$0.97|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.64|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||N/A|
|1 month (2021-09-20)||5.83%|
|3 months (2021-07-23)||6.86%|
|6 months (2021-04-23)||45.33%|
|1 year (2020-10-23)||37.38%|
|2 years (2019-10-23)||51.39%|
|3 years (2018-10-23)||2.97|
|5 years (2016-10-21)||2.8|
|Revenue TTM||$16.5 million|
|Gross profit TTM||$1.6 million|
|Return on assets TTM||-59.12%|
|Return on equity TTM||-270.65%|
|Market capitalisation||$168.2 million|
TTM: trailing 12 months
There are currently 9.6 million Adamis Pharmaceuticals Corporation shares held short by investors – that's known as Adamis Pharmaceuticals Corporation's "short interest". This figure is 0.9% down from 9.7 million last month.
There are a few different ways that this level of interest in shorting Adamis Pharmaceuticals Corporation shares can be evaluated.
Adamis Pharmaceuticals Corporation's "short interest ratio" (SIR) is the quantity of Adamis Pharmaceuticals Corporation shares currently shorted divided by the average quantity of Adamis Pharmaceuticals Corporation shares traded daily (recently around 1.8 million). Adamis Pharmaceuticals Corporation's SIR currently stands at 5.41. In other words for every 100,000 Adamis Pharmaceuticals Corporation shares traded daily on the market, roughly 5410 shares are currently held short.
However Adamis Pharmaceuticals Corporation's short interest can also be evaluated against the total number of Adamis Pharmaceuticals Corporation shares, or, against the total number of tradable Adamis Pharmaceuticals Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adamis Pharmaceuticals Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Adamis Pharmaceuticals Corporation shares in existence, roughly 60 shares are currently held short) or 0.0648% of the tradable shares (for every 100,000 tradable Adamis Pharmaceuticals Corporation shares, roughly 65 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adamis Pharmaceuticals Corporation.
Find out more about how you can short Adamis Pharmaceuticals Corporation stock.
We're not expecting Adamis Pharmaceuticals Corporation to pay a dividend over the next 12 months.
Adamis Pharmaceuticals Corporation's shares were split on a 1:17 basis on 12 December 2013. So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adamis Pharmaceuticals Corporation shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for Adamis Pharmaceuticals Corporation shares which in turn could have impacted Adamis Pharmaceuticals Corporation's share price.
Over the last 12 months, Adamis Pharmaceuticals Corporation's shares have ranged in value from as little as $0.387 up to $1.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adamis Pharmaceuticals Corporation's is 1.3497. This would suggest that Adamis Pharmaceuticals Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.